专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

GB202103542D0 Safety signs 未知
公开(公告)号：GB202103542D0
公开(公告)日：2021-04-28
申请号：GB202103542
申请日：2021-03-15
申请人： MILBURN MICHAEL

2. 发明专利

GB202112467D0 Screen guard 未知
公开(公告)号：GB202112467D0
公开(公告)日：2021-10-13
申请号：GB202112467
申请日：2021-09-01
申请人： MILBURN MICHAEL

3. 发明申请

WO2021262696A2 METHODS FOR SELECTING AND TREATING CANCER WITH FGFR3 INHIBITORS 审中-公开
公开(公告)号：WO2021262696A2
公开(公告)日：2021-12-30
申请号：PCT/US2021/038446
申请日：2021-06-22
申请人： GENECENTRIC THERAPEUTICS, INC. , THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL , MILBURN, Michael , MAYHEW, Greg , EISNER, Joel
发明人： PEROU, Charles
IPC分类号： A61P35/00 , C12Q1/6886 , C12Q1/6869 , C12Q1/6809 , A61K31/00 , A61K39/0011 , A61K47/50
摘要： Provided herein are FGFR3 activation signatures for use in methods and compositions for predicting the response of a subject suffering from cancer to FGFR3 inhibitor therapy.

4. 发明申请

WO2010091290A1 DETERMINATION OF THE LIVER TOXICITY OF AN AGENT 审中-公开
标题翻译：确定代谢物的肝脏毒性
公开(公告)号：WO2010091290A1
公开(公告)日：2010-08-12
申请号：PCT/US2010/023372
申请日：2010-02-05
申请人： METABOLON, INC. , MILBURN, Michael , GUO, Lining , WULFF, Jacob, Edward , LAWTON, Kay, A.
发明人： MILBURN, Michael , GUO, Lining , WULFF, Jacob, Edward , LAWTON, Kay, A.
IPC分类号： C12Q1/68
CPC分类号： G01N33/5014 , G01N33/5067 , G01N33/5088
摘要： The present invention provides various biomarkers for hepatotoxicity and various methods of using the biomarkers Some of the biomarkers within the scope of this invention are cholate, glycochenodeoxycholate, glycocholate, taurine, 3-hyroxy-2-ethylpropιonate, 4- imidazoleacetate, tyramine, anthranilate, 2'-deoxycytιdιne, N-acetyl aspartate (NAA), beta-hydroxyhexanoate, and sarcosine (N- methylglycine) The methods of using the biomarkers include exposing a first hepatocyte culture to a test agent and comparing the levels of the one or more biomarkers obtained in the first hepatocyte culture to the levels of the one or more biomarkers obtained in a second hepatocyte culture without the test agent, where differential levels of the one or more biomarkers in the first hepatocyte culture as compared to the levels in the second hepatocyte culture is indicative of the test agent being a hepatotoxicant.
摘要翻译：本发明提供用于肝毒性的各种生物标志物和使用生物标志物的各种方法本发明范围内的一些生物标志物是胆酸，甘氨脱氧胆酸，甘胆酸盐，牛磺酸，3-羟基-2-乙基丙酸，4-咪唑乙酸盐，酪胺，邻氨基苯甲酸酯，2'-脱氧胞苷，N-乙酰天冬氨酸（NAA），β-羟基己酸酯和肌氨酸（N-甲基甘氨酸）使用生物标志物的方法包括将第一次肝细胞培养物暴露于测试试剂并比较在第一肝细胞培养物中获得的一种或多种生物标志物在没有测试剂的第二肝细胞培养物中获得的一种或多种生物标志物的水平，其中第一肝细胞培养物中的一种或多种生物标志物的差异水平与第二次肝细胞培养物中的水平指示测试试剂是肝毒素。

5. 发明申请

WO2006127987A2 TREATMENT OF EYE DISORDERS WITH SIRTUIN MODULATORS 审中-公开
标题翻译：用SIRTUIN调节剂治疗眼部疾病
公开(公告)号：WO2006127987A2
公开(公告)日：2006-11-30
申请号：PCT/US2006/020406
申请日：2006-05-24
申请人： SIRTRIS PHARMACEUTICALS, INC. , MILBURN, Michael , WESTPHAL, Christoph, H. , LIVINGSTON, David, J. , LAMBERT, Philip , NORMINGTON, Karl, D. , ELLIOTT, Peter
发明人： MILBURN, Michael , WESTPHAL, Christoph, H. , LIVINGSTON, David, J. , LAMBERT, Philip , NORMINGTON, Karl, D. , ELLIOTT, Peter
CPC分类号： A61K31/05 , A61K31/353
摘要： Sirtuin modulators, particularly sirtuin activators, are useful in treating vision impairment. In general, the sirtuin modulators inhibit the progression of vision impairment resulting from various eye disorders. The invention also includes pharmaceutically acceptable formulations of sirtuin modulators, particular ophthalmically acceptable formulations.
摘要翻译： Sirtuin调节剂，特别是sirtuin活化剂，可用于治疗视力障碍。通常，瑟土因调节剂抑制由各种眼病引起的视力障碍的进展。本发明还包括沉默调节蛋白调节剂的药学上可接受的制剂，特别是眼科上可接受的制剂。

6. 发明申请

WO2006076681A2 NOVEL COMPOSITIONS FOR PREVENTING AND TREATING NEURODEGENERATIVE AND BLOOD COAGULATION DISORDERS 审中-公开
标题翻译：用于预防和治疗神经损伤和血液凝血障碍的新型组合物
公开(公告)号：WO2006076681A2
公开(公告)日：2006-07-20
申请号：PCT/US2006/001428
申请日：2006-01-13
申请人： SIRTRIS PHARMACEUTICALS, INC. , MILBURN, Michael , MILNE, Jill , WESTPHAL, Christopher, H. , NORMINGTON, Karl, D. , FUJII, Jennifer , DIPP, Michelle , ELLIOT, Peter
发明人： MILBURN, Michael , MILNE, Jill , WESTPHAL, Christopher, H. , NORMINGTON, Karl, D. , FUJII, Jennifer , DIPP, Michelle , ELLIOT, Peter
CPC分类号： A61K31/065 , A61K31/05 , A61K31/353 , A61K31/7048
摘要： Provided herein are methods and compositions for treating or preventing neurodegenerative disorders or blood coagulation disorders. Methods may comprise modulating the activity or level of a sirtuin, such as SIRTl or Sir2. Exemplary methods comprise contacting a cell with a sirtuin activating compound, such as a flavone, stilbene, flavanone, isoflavone, catechin, chalcone, tannin or anthocyanidin; or an inhibitory compound, such as nicotinamide.
摘要翻译：本文提供了用于治疗或预防神经变性疾病或血液凝固障碍的方法和组合物。方法可以包括调节sirtuin的活性或水平，例如SIRT1或Sir2。示例性方法包括使细胞与沉默调节蛋白激活化合物如黄酮，芪，黄酮酮，异黄酮，儿茶素，查耳酮，单宁或花色素接触; 或抑制性化合物，例如烟酰胺。

7. 发明申请

WO2013006278A3 IDENTITY ELUCIDATION OF UNKNOWN METABOLITES 审中-公开
标题翻译：未知代谢物的身份验证
公开(公告)号：WO2013006278A3
公开(公告)日：2013-04-04
申请号：PCT/US2012043461
申请日：2012-06-21
申请人： METABOLON INC , HELMHOLTZ ZENTRUM MUENCHEN , MILBURN MICHAEL , KASTENMUELLER GABRIELE , KRUMSIEK JAN , SUHRE KARSTEN
发明人： MILBURN MICHAEL , KASTENMUELLER GABRIELE , KRUMSIEK JAN , SUHRE KARSTEN
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6872 , C12Q1/68 , C12Q1/6883 , C12Q1/6886 , G01N33/6848 , G01N2570/00 , G01N2800/7066
摘要： A method of elucidating the identity of an unknown metabolite comprising measuring amounts of known and unknown metabolites in subjects; associating the unknown metabolite with a specific gene from a gene association study; determining a protein associated with the specific gene and analyzing information for the protein; associating the unknown metabolite with concentrations and/or ratios of other metabolites in subjects; obtaining chemical structural data for the unknown metabolite; and using the information obtained to elucidate the identity of the unknown metabolite.
摘要翻译：一种阐明未知代谢物身份的方法，包括测量受试者中已知和未知代谢物的量; 将未知代谢物与来自基因关联研究的特定基因相关联; 确定与特定基因相关的蛋白质并分析蛋白质的信息; 将未知代谢物与受试者中其他代谢物的浓度和/或比率相关联; 获得未知代谢物的化学结构数据; 并使用获得的信息来阐明未知代谢物的身份。

8. 发明申请

WO2006094210A3 TETRAHYDROQUINOXALINONE SIRTUIN MODULATORS 审中-公开
标题翻译：四氢喹诺酮类SIRTUIN调节剂
公开(公告)号：WO2006094210A3
公开(公告)日：2007-03-29
申请号：PCT/US2006007656
申请日：2006-03-03
申请人： SIRTRIS PHARMACEUTICALS INC , MILNE JILL , NORMINGTON KARL D , MILBURN MICHAEL
发明人： MILNE JILL , NORMINGTON KARL D , MILBURN MICHAEL
IPC分类号： C07D413/14 , A61K31/498 , C07D413/12 , C07D487/04
CPC分类号： C07D487/04 , C07D413/12 , C07D413/14
摘要： Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benfit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
摘要翻译：本文提供了新的沉默调节蛋白的调节化合物及其使用方法。沉默调节蛋白的调节化合物可用于增加细胞的寿命，以及治疗和/或预防各种各样的疾病和病症，包括例如与老化或紧张相关的疾病或病症，糖尿病，肥胖症，神经变性疾病，心血管疾病，凝血障碍，炎症，癌症和/或潮红以及由线粒体活性增加所致的疾病或病症。还提供了包含与另一种治疗剂组合的沉默调节蛋白的调节化合物的组合物。

9. 发明申请

WO2007008548A2 METHODS AND RELATED COMPOSITIONS FOR TREATING OR PREVENTING OBESITY, INSULIN RESISTANCE DISORDERS, AND MITOCHONDRIAL-ASSOCIATED DISORDERS 审中-公开
标题翻译：用于治疗或预防肥胖，胰岛素抵抗障碍和线粒体相关障碍的方法和相关组合物
公开(公告)号：WO2007008548A2
公开(公告)日：2007-01-18
申请号：PCT/US2006/026272
申请日：2006-07-07
申请人： SIRTRIS PHARMACEUTICALS, INC. , MILBURN, Michael , MILNE, Jill , AUWERX, Johan , ARGMANN, Carmen , LAGOUGE, Marie , DIPP, Michelle
发明人： MILBURN, Michael , MILNE, Jill , AUWERX, Johan , ARGMANN, Carmen , LAGOUGE, Marie , DIPP, Michelle
IPC分类号： A61K31/05 , A61P3/04
CPC分类号： A61K31/05
摘要： Provided herein are methods and compositions for treating or preventing metabolic disorders, such as obesity and diabetes. Methods may comprise modulating the activity or level of a sirtuin, such as SIRTl or Sir2. Exemplary methods comprise contacting a cell with a sirtuin activating compound, such as a flavone, stilbene, flavanone, isoflavone, catechin, chalcone, tannin or anthocyanidin, or an inhibitory compound, such as nicotinamide.
摘要翻译：本文提供了用于治疗或预防代谢病症例如肥胖症和糖尿病的方法和组合物。方法可以包括调节sirtuin如SIRT1或Sir2的活性或水平。示例性的方法包括使细胞与沉默调节蛋白的活性化合物例如黄酮，s，黄烷酮，异黄酮，儿茶素，查耳酮，单宁或花色素或抑制性化合物如烟酰胺接触。

10. 发明申请

WO2006105440A3 NICOTINAMIDE RIBOSIDE AND ANALOGUES THEREOF 审中-公开
公开(公告)号：WO2006105440A3
公开(公告)日：2006-10-05
申请号：PCT/US2006/012076
申请日：2006-03-30
申请人： SIRTRIS PHARMACEUTICALS, INC. , MILBURN, Michael , MILNE, Jill , NORMINGTON, Karl, D. , NUNES, Joseph, J. , SALZMANN, Thomas , SINCLAIR, David , WESTPHAL, Christoph, H.
发明人： MILBURN, Michael , MILNE, Jill , NORMINGTON, Karl, D. , NUNES, Joseph, J. , SALZMANN, Thomas , SINCLAIR, David , WESTPHAL, Christoph, H.
IPC分类号： A61K31/445 , C07H7/06 , C07H19/048 , A61P39/00
摘要： Provided herein are sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式